Trial Profile
A Phase Ib Study of AZD6738 for Patients With Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia Progressing on Front-Line Therapy
Status:
Recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 19 Mar 2024
Price :
$35
*
At a glance
- Drugs Ceralasertib (Primary)
- Indications Chronic myelomonocytic leukaemia; Myelodysplastic syndromes
- Focus Adverse reactions
- 12 Mar 2024 Planned primary completion date changed from 31 May 2022 to 31 May 2024.
- 17 Jun 2022 Results assessing inhibition of ATR in patients with MDS or CMML, particularly those who harbor SF gene mutations, presented at the 27th Congress of the European Haematology Association.
- 14 Dec 2021 Results of Safety and Preliminary Activity from a Phase Ib/II Study presented at the 63rd American Society of Hematology Annual Meeting and Exposition